Schrodinger Financials - Benzinga

Schrodinger Inc

SDGRNASDAQ

Trade with Public

Trade with Public

$29.45

0.220.75%

近くで: Sep 23, 5:00 PM EST

$29.57

0.341.16%

プレマーケット: 4:09 AM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Schrodinger Financials

Schrodinger (SDGR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Schrodinger Sees FY Drug Discovery Revenue At $65M-$75M

Schrodinger (NASDAQ:SDGR) Sees Drug discovery revenue is expected to range from $65 million to $75 million.

Benzinga Newsdesk

PRO
Schrodinger Q2 Adj. EPS $0.08 Beats $(0.48) Estimate, Sales $58.889M Beat $47.228M Estimate

Benzinga Newsdesk

PRO
Schrodinger Reaffirms FY And Q2 2026 Financial And Operational Guidance

Benzinga Newsdesk

PRO
Schrodinger Affirms FY2026 Sales Guidance of $273.000M-$293.000M vs $252.752M Est

Schrodinger (NASDAQ:SDGR) affirms FY2026 sales outlook from $273.000 million-$293.000 million to $273.000 million-$293.000 million vs $252.752 million estimate.

Benzinga Newsdesk

PRO
Schrodinger Q1 Adj. EPS $(0.63), Inline, Sales $58.587M Beat $48.002M Estimate

Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.63) per share which met the analyst consensus estimate. This is a 1.56 percent increase over losses of $(0.64) per share from the same period last year. The

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved